SkinBioTherapeutics plc (LON:SBTX – Get Free Report) shares reached a new 52-week low on Monday. The company traded as low as GBX 4.50 and last traded at GBX 4.71, with a volume of 190,895 shares. The stock had previously closed at GBX 5.
SkinBioTherapeutics Trading Down 5.7%
The firm has a market capitalization of £12.22 million, a price-to-earnings ratio of -29.47 and a beta of 0.10. The company has a fifty day moving average price of GBX 6.75 and a two-hundred day moving average price of GBX 9.90. The company has a current ratio of 6.14, a quick ratio of 10.01 and a debt-to-equity ratio of 11.77.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
See Also
- Five stocks we like better than SkinBioTherapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
